Goenka, Niru, Kotonya, Christina, Penney, Michael D., Randeva, Harpal S. and O'Hare, J. Paul. (2008) Thiazolidinediones and the renal and hormonal response to water immersion-induced volume expansion in type 2 diabetes mellitus. American Journal of Physiology: Endocrinology and Metabolism, Volume 294 (Number 4). E733-E739. ISSN 0193-1849

Full text not available from this repository.

Abstract

Thiazolidinediones cause sodium retention and edema by a direct effect on the kidneys. The aim of this study was to use the technique of head-out water immersion to investigate the effects of rosiglitazone on sodium and volume homeostasis in subjects with type 2 diabetes mellitus. The volume expansion response to water immersion was compared with the response on a non-immersion control day in 12 nondiabetic male subjects and 8 diet-controlled male type 2 diabetic subjects with hourly blood and urine sampling over a 4-h period. This was repeated after both groups had taken 4 mg of rosiglitazone daily for 7 days. Immersion produced a natriuresis in both groups (P < 0.001). An impairment of this natriuresis was seen in the diabetic subjects (P = 0.006). However, when rosiglitazone was taken, there was no significant difference in immersion-induced natriuresis compared with nondiabetic controls (P = 0.2). There was an immersion-induced rise in atrial natriuretic peptide (ANP) and urinary cyclic guanosine monophosphate (cGMP), in the healthy subjects (ANP P = 0.001, cGMP P = 0.043), which was not seen in the diabetic subjects (ANP P = 0.51, cGMP P = 0.74). Rosiglitazone restored the immersion-induced increase in cGMP excretion and rise of ANP in the diabetic group (ANP P = 0.048, cGMP P = 0.009). This study confirms that type 2 diabetic subjects have an impaired natriuretic response to acute volume expansion, which appears to be enhanced rather than diminished by rosiglitazone. This may be related to its effects in increasing natriuretic peptides and restoring the impaired cGMP excretion to volume expansion.

Item Type:	Journal Article
Subjects:	R Medicine > RC Internal medicine Q Science > QP Physiology
Divisions:	Faculty of Medicine > Warwick Medical School > Metabolic and Vascular Health Faculty of Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH):	Non-insulin-dependent diabetes, Rosiglitazone, Atrial natriuretic peptides, Renin, Aldosterone, Cyclic guanylic acid
Journal or Publication Title:	American Journal of Physiology: Endocrinology and Metabolism
Publisher:	American Physiological Society
ISSN:	0193-1849
Date:	April 2008
Volume:	Volume 294
Number:	Number 4
Number of Pages:	7
Page Range:	E733-E739
Identification Number:	10.1152/ajpendo.00583.2007
Status:	Peer Reviewed
Publication Status:	Published
Access rights to Published version:	Open Access
Funder:	GlaxoSmithKline, Diabetes, Endocrine and Immersion Research Trust
References:	1. Arborelius M Jr, Ballidin UI, Lilja B, Lundgren CE. Hemodynamic changes in man during immersion with the head above water. Aerosp Med 43: 592–598, 1972. 2. Barbato A, Cappuccio FP, Folkerd EJ, Strazzullo P, Sampson B, Cook DG, Alberti KG. Metabolic syndrome and renal sodium handling in three ethnic groups living in England. Diabetologia 47: 40–46, 2004. 3. Cappuccio FP, Markandu ND, Buckley MG, Sagnella GA, Shore AC, MacGregor GA. Changes in the plasma levels of atrial natriuretic peptides during mineralocorticoid escape in man. Clin Sci (Lond) 72: 531– 539, 1987. 4. De Chatel R, Toth M, Barna I, Tisler A. Body sodium, atrial natriuretic peptide and blood pressure in diabetes mellitus. Acta Biomed Ateneo Parmense 63: 153–161, 1992. 5. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi- Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROACTIVE Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366: 1279–1289, 2005. 6. Dulawa J, Kokot F, Klin M, Bar A, Grzeszczak W, Darocha Z. [Studies of atrial natriuretic peptide, diuresis and natriuresis in patients with diabetes mellitus types 1 and 2 after water immersion]. Pol Arch Med Wewn 83: 166–176, 1990. 7. Epstein M. Renal effects of head-out water immersion in humans: a 15-year update. Physiol Rev 72: 563–621, 1992. 8. Epstein M, Duncan DC, Fishman LM. Characterization of the natriuresis caused in normal man by immersion in water. Clin Sci 43: 275–287, 1972. 9. Epstein M, Norsk P, Loutzenhiser R. Effects of water immersion on atrial natriuretic peptide release in humans. Am J Nephrol 9: 1–24, 1989. 10. Epstein M, Saruta T. Effect of water immersion on renin-aldosterone and renal sodium handling in normal man. J Appl Physiol 31: 368–374, 1971. 11. Hansen L, Ekstrom CT, Tabanera YPR, Anant M, Wassermann K, Reinhardt RR. The Pro12Ala variant of the PPARG gene is a risk factor for peroxisome proliferator-activated receptor-gamma/alpha agonist-induced edema in type 2 diabetic patients. J Clin Endocrinol Metab 91: 3446–3450, 2006. 12. Hollenberg NK. Considerations for management of fluid dynamic issues associated with thiazolidinediones. Am J Med 115, Suppl 8A: 111S–115S, 2003. 13. Johansen LB, Foldager N, Stadeager C, Kristensen MS, Bie P, Warberg J, Kamegai M, Norsk P. Plasma volume, fluid shifts, and renal responses in humans during 12 h of head-out water immersion. J Appl Physiol 73: 539–544, 1992. 14. Karalliedde J, Buckingham R, Starkie M, Lorand D, Stewart M, Viberti G. Effect of various diuretic treatments on rosiglitazone-induced fluid retention. J Am Soc Nephrol 17: 3482–3490, 2006. 15. Khan O, Riazi S, Hu X, Song J, Wade JB, Ecelbarger CA. Regulation of the renal thiazide-sensitive Na-Cl cotransporter, blood pressure, and natriuresis in obese Zucker rats treated with rosiglitazone. Am J Physiol Renal Physiol 289: F442–F450, 2005. 16. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and betacell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412–419, 1985. 17. Morris AD, Petrie JR, Connell JM. Insulin and hypertension. J Hypertens 12: 633–642, 1994. 18. Nannipieri M, Seghieri G, Catalano C, Prontera T, Baldi S, Ferrannini E. Defective regulation and action of atrial natriuretic peptide in type 2 diabetes. Horm Metab Res 34: 265–270, 2002. 19. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 27: 256–263, 2004. 20. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356: 2457–2471, 2007. 21. O’Hare JP, Anderson JV, Millar ND, Dalton N, Tymms DJ, Bloom SR, Corrall RJ. Hormonal response to blood volume expansion in diabetic subjects with and without autonomic neuropathy. Clin Endocrinol (Oxf) 30: 571–579, 1989. 22. O’Hare JP, Roland JM, Walters G, Corrall RJ. Impaired sodium excretion in response to volume expansion induced by water immersion in insulin-dependent diabetes mellitus. Clin Sci (Lond) 71: 403–409, 1986. 23. Penney MD, Hampton D, Oleesky DA, Livingstone C, Mulkerrin E. Radioimmunoassays of arginine vasopressin and atrial natriuretic peptide: application of a common protocol for plasma extraction using Sep-Pak C18 cartridges. Ann Clin Biochem 29: 652–658, 1992. 24. Raji A, Seely EW, Bekins SA, Williams GH, Simonson DC. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care 26: 172–178, 2003. 25. Salas-Ramirez M, Ariza Andraca R, Frati Munari A, Munoz H, Altamirano P. Effect of plasma volume expansion on auricular natriuretic peptide in non-dependent insulin diabetic patients with autonomic neuropathy. Arch Med Res 26: 35–40, 1995. 26. Singh S, Loke YK, Furberg CD. Thiazolidinediones and Heart Failure: A Teleo-Analysis. Diabetes Care, 2007. 27. Stefanski A, Majkowska L, Ciechanowicz A, Frankow M, Safranow K, Parczewski M, Moleda P, Pilarska K. Association between the Pro12Ala variant of the peroxisome proliferator-activated receptor-gamma2 gene and increased 24-h diastolic blood pressure in obese patients with type II diabetes. J Hum Hypertens 20: 684–692, 2006. 28. Walley T, Hughes D, Kendall H. Trends and influences on use of antidiabetic drugs in England, 1992–2003. Pharmacoepidemiol Drug Saf 14: 769–773, 2005. 29. Wang TD, Chen WJ, Lin JW, Chen MF, Lee YT. Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome. Am J Cardiol 93: 362–365, 2004. 30. Weidmann P, Ferrari P. Central role of sodium in hypertension in diabetic subjects. Diabetes Care 14: 220–232, 1991. 31. Zanchi A, Chiolero A, Maillard M, Nussberger J, Brunner HR, Burnier M. Effects of the peroxisomal proliferator-activated receptorgamma agonist pioglitazone on renal and hormonal responses to salt in healthy men. J Clin Endocrinol Metab 89: 1140–1145, 2004. 32. Zhang H, Zhang A, Kohan DE, Nelson RD, Gonzalez FJ, Yang T. Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention. Proc Natl Acad Sci USA 102: 9406–9411, 2005. 33. Zimmerman RS, Edwards BS, Schwab TR, Heublein DM, Burnett JC Jr. Atrial natriuretic peptide during mineralocorticoid escape in the human. J Clin Endocrinol Metab 64: 624–627, 1987.
URI:	http://wrap.warwick.ac.uk/id/eprint/30311

Data sourced from Thomson Reuters' Web of Knowledge

Request changes to a record

Actions (login required)

View Item